New Data Show Theratechnologies’ SORT1+ Technology Is Effective In Many Treatment-Resistant Cancers

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor  Curcumin shows increased anticancer activity when conjugated to proprietary peptide  SORT1+ technology significantly widens therapeutic window of traditional cytotoxic cancer treatments  Montreal, Canada – June 22, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a …Lire la suite

Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904 New peptide-curcumin conjugate, TH1901, shows 100 times greater anti-cancer cell proliferation activity than unconjugated curcumin in vitro Results to be presented at American Association for Cancer Research (AACR) Virtual Annual Meeting II Montreal, Canada – May 15, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: …Lire la suite

Theratechnologies Announces New Positive Results For Two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer

TH1902 and TH1904 more effective and safer in vivo compared to current standard ovarian cancer treatments  New data presented during the AACR Virtual Annual Meeting Montreal, Canada – April 27, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that new positive results about its two investigational peptide-drug conjugates …Lire la suite

Theratechnologies To Make Oral Presentation On Oncology Platform During AACR Virtual Annual Meeting

Montreal, Canada – April 16, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it will make an oral presentation on new results from its sortilin targeting oncology platform during a virtual session of the annual meeting of the American Association for Cancer Research (AACR).

Theratechnologies Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Montreal, Canada – April 16, 2020 – Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, the current President and Chief Executive Officer of Theratechnologies, was granted 487,421 stock options, or Options, to purchase an aggregate of 487,421 common  shares of Theratechnologies under Nasdaq Listing Rule 5635(c)(4). …Lire la suite

Theratechnologies Announces Financial Results For The First Quarter of 2020

Montreal, Canada – April 14, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the first quarter ended February 29, 2020.  First quarter 2020 financial highlights First quarter net sales of $15,719,000, up 4.1% from the same quarter last year Trogarzo® sales up 17.4% from …Lire la suite

Theratechnologies Provides Business Update Related To Current Covid-19 Situation

Supply chain remains intact with ample inventory of commercial medicines Research and development activities currently progressing Company withdraws 2020 financial guidance until further notice Montreal, Canada – March 31, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today issued an update on the Company’s activities in relation to the current …Lire la suite

Visceral Fat Is A Predictor Of Liver Fibrosis And Fibrosis Progression In People Living With HIV

Montreal, Canada – March 11, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that Dr. Lindsay Fourman, from Harvard Medical School, presented data demonstrating that visceral fat is a clinical predictor of liver fibrosis and liver fibrosis progression in an oral presentation during CROI 2020. These …Lire la suite